$AXSM News

Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should Know

Piper Sandler Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $238

Does Axsome Therapeutics (AXSM) Trade Above Fair Value On Sales?

RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $295

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

Why Baird Sees Growth Potential in Axsome Therapeutics, Inc. (AXSM)

Deutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267

Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247

$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today

Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day

Axsome Therapeutics Highlights Alzheimer’s Agitation Impact In Shared Goals Survey

Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction

Axsome Therapeutics (AXSM) Stock Looks Undervalued As Its 5 Year 7x Run Continues

Is Axsome Therapeutics’ (AXSM) New CNS Data Enough To Reinforce Its Neuropsychiatric Portfolio Story?

Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference

Axsome Therapeutics (AXSM) Reported New Clinical Data In Depression And Alzheimer’s Agitation

Piper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026

Axsome Therapeutics, Inc. (AXSM) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript